| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00141310 Details | 2021-02-01 Interventional | 2 | - | Sildenafil Citr… Eclampsia Pre-Eclampsia Pre-eclampsia | Study prematurely discont'd 20-Apr-2006 after interim analysis suggested sample size could be
reduced without losing power. No safety concerns led to decision. - | |||
| NCT00150306 Details | 2021-01-29 Interventional | 3 | - | Sertraline Stress Disorder… Stress Disorder… | Please see Detailed Description below for termination reason. - | |||
| NCT03055312 Details | 2021-01-28 Interventional | 3 | 36 | Bicalutamide Breast Neoplasm… Triple Negative… Metastatic Trip… | - - | |||
| NCT01838044 Details | 2021-01-28 Interventional | 4 | 180 | Celecoxib Pregabalin Back Pain Low Back Pain Chronic Low Bac… | Recruitment terminated on 3Apr2015 due to slow recruitment rate and lack of operational
feasibility. Study was not terminated for reasons of safety/efficacy. The study was terminated as it had been determined that it was no longer operationally feasible to continue the trial. The study termination was not due to a safety issue or finding. | |||
| NCT01302938 Details | 2021-01-28 Interventional | 4 | 18 | Tolterodine Tar… Urinary Bladder… Overactive Blad… | Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No
new safety issues were identified. The study was terminated prematurely due to low participant enrollment and due to relatively small sample size; results should be interpreted with caution. Early termination of the study was not related to any safety concern. | |||
| NCT01145417 Details | 2021-01-28 Interventional | 3 | 217 | Pregabalin Neuralgia HIV-1 Infection Neuropathic Pai… | See termination reason in detailed description. The parent double blind trial A0081244 (NCT01049217) was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated. | |||
| NCT01049217 Details | 2021-01-28 Interventional | 3 | 377 | Pregabalin Neuralgia Peripheral Nerv… Neuropathy | See termination reason in detailed description. Based on Data Monitoring Committee (DMC) interim efficacy analysis results indicating a low probability for success, the study was terminated on April 2, 2012; the termination was unrelated to any safety findings that could impact participant health. | |||
| NCT00905437 Details | 2021-01-28 Interventional | 3 | 72 | Pregabalin Pain, Periopera… | The Study was terminated on May 24th 2012 due to a slow recruitment rate. The study was not
terminated for reasons of safety or efficacy. As the enrollment rate was very low, the study was prematurely terminated. The number of enrolled participants was too low for meaningful formal statistical conclusions. | |||
| NCT00635531 Details | 2021-01-28 Interventional | 4 | 16 | Alprazolam Panic Disorder | Please see Detailed Description for termination reason. - | |||
| NCT00635076 Details | 2021-01-28 Interventional | 4 | 3 | Alprazolam Panic Disorder | Please see Detailed Description for the termination reason. - | |||
| NCT00634790 Details | 2021-01-28 Interventional | 4 | 49 | Alprazolam Panic Disorder | Please see Detailed Description for termination reason. - | |||
| NCT02282514 Details | 2021-01-27 Interventional | 1/2 | [1 Refs] | 23 | Cyclophosphamid… Methylprednisol… Methylprednisol… Rituximab Thymoglobulin Stiff-Person Sy… Syndrome | Could not predict who would respond, relapse or go into remission - | ||
| NCT00766142 Details | 2021-01-26 Interventional | 2 | [1 Refs] | 18 | Calcium Cetuximab Fluorouracil Leucovorin Levoleucovorin Oxaliplatin Carcinoma Colorectal Neop… Peritoneal Neop… Colorectal Canc… Primary Periton… | In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such,
eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown
down considerably, and the trial was stopped. - | ||
| NCT03339401 Details | 2021-01-25 Interventional | 2 | 29 | Brincidofovir Adenoviridae In… Adenovirus | terminated due to low enrollment rate The study was terminated in May 2019 due to poor subject accrual rates. As a result, statistical analyses were not performed. Limited demographic, efficacy, and safety data are provided for the 29 subjects who were enrolled as descriptive summaries. | |||
| NCT00407797 Details | 2021-01-25 Interventional | 4 | 136 | Pregabalin Seizures Partial Seizure… | - - | |||
| NCT04456088 Details | 2021-01-22 Interventional | 2 | 0 | Nitric Oxide COVID-19 Coronavirus Inf… Pneumonia, Vira… Respiration Dis… Respiratory Tra… Corona Virus In… Respiratory Dis… SARS-CoV 2 | Terminated (halted prematurely) - | |||
| NCT02602210 Details | 2021-01-22 Interventional | 3 | 100 | Hydrocortisone Hydrocortisone … Fibrosis Liver Cirrhosis Sepsis | low inclusion rate - | |||
| NCT02446886 Details | 2021-01-22 Interventional | 4 | 15 | Adrenocorticotr… Hormones Melanocyte-Stim… beta-Endorphin Multiple Sclero… Sclerosis | Slow enrollment - | |||
| NCT01702558 2012-001547-46 Details | 2021-01-22 Interventional | 2 | 182 | Ado-Trastuzumab… Capecitabine Maytansine Trastuzumab Breast Neoplasm… Stomach Neoplas… Breast Cancer Gastric Cancer | The sponsor decided to terminate study after 70% of participants had experienced a
progression-free survival event. The sponsor decided to terminate the study after 70% of participants had experienced a PFS event. Participants were allowed to continue treatment by enrolling into study NCT00781612 or by moving to commercial drug, depending on their country. | |||
| NCT00738777 2008-000644-13 Details | 2021-01-22 Interventional | 2 | - | Anastrozole Fulvestrant Tamoxifen Breast Neoplasm… Breast Cancer | in preparation for an amendment - |